Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Expert Content
  4.  » Spray-Drying Process for Scale up and Commercialization
Icon of a document with a pencil

Spray-Drying Process for Scale up and Commercialization

Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. In a recent Pharmaceutical Technology webcast, Jon Scrafford, Associate Director of Process Engineering at Catalent, and Ryan Minikis, Principal at Arclight  Pharmaceuticals, LLC, explored the use of spray drying to create amorphous solid dispersions (ADSs) and the optimization of process parameters for successful scale-up to commercial manufacture of the final dosage form. Here, Scrafford and Minikis answer several key questions posed by audience members during the Pharmaceutical Technology webcast.

Click here to view the Q&A article